Sten R. Sörensen, Chairman
Currently also CEO at Cereno Scientific AB and Chairman of the Board at Stayble Therapeutics AB and AcuCort AB. Seasoned professional with international experience in a variety of sectors including Pharmaceutical, Biotechnology, Finance, Renewable Energy and Management Consulting. Assignments include senior global positions at AstraZeneca and Monsanto/GD Searle, CEO and Board member at Pharma Start Up Cortendo, Sector Head Life Science, Med Tech, Pharma & Private Equity at PwC, VP Bus Dev and Board Member at Eurowind.
View Sten Sörensen’s LinkedIn profile
Assoc. Prof. Johan Kördel, Board Director
Senior Partner at Lundbeckfonden Ventures and board member of Acacia Pharma, BoneSupport, Enterome, Iconic Therapeutics, River Vision, VHsquared and Ziarco. He was previously co-founder and CEO of Sound Biotech ApS and co-founder and Senior Vice President of Research and Business Development of Biovitrum AB. Prior to these positions Johan worked a decade in the pharmaceutical company Pharmacia with management, research, early development, portfolio management, business development and alliance management. He is an associate professor in Physical Chemistry at Lund University, Sweden.
View Johan Kördel’s LinkedIn profile
Jens Knobe, Board Director
Senior Vice President Product & Market Development at Getinge Infection Control in the Getinge Group. Jens has 25 years of experience of driving growth in the life science and telecom industries.
View Jens Knobe's LinkedIn profile
Prof. Mikael Akke, Board Director
Director NMR services and co-founder of SARomics Biostructures AB. Professor, Professor of Physical Chemistry at Lund University since 2005. He is an expert in biomolecular NMR spectroscopy. His current research includes fundamental studies of the driving forces underlying ligand binding.
View Mikael's LinkedIn profile
Dr. Björn Walse, Board Director
Co-founder and CEO of SARomics Biostructures AB and has over 15 years of drug discovery and research management experience from the biotech industry. His main focus area is structural biology and structure-based drug design and he has been involved in numerous early stage drug discovery projects.
View Björn's LinkedIn profile